12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ALX-0171: Phase I started

Ablynx began an open-label, German Phase I trial to evaluate single escalating-doses and repeated inhalations of ALX-0171 in about 24 adults with...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >